December 5, 2023
The Globe and Mail | Xenon stock surges as B.C. biotech’s epilepsy drug shows promise for treating depression
David Martin, Managing Director and Head of Bloom Burton Equity Research comments in The Globe and Mail on the latest development from Xenon Pharmaceutical’s flagship molecule, XEN1101.
Ian Mortimer, President and Chief Executive Officer of Xenon Pharmaceuticals and his team were honoured earlier this year at the 2023 Bloom Burton Award Gala.
